Loading
A phase 1/2 trial of TAC01-CLDN18.2 in advanced solid tumours, run by Triumvira Immunologics, Inc., active and no longer recruiting.
TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) is a phase 1/2 interventional study registered as NCT05862324 by Triumvira Immunologics, Inc., with 113 participants enrolled, started 2023-08-23 and due to reach its primary completion in 2027-08-01. Interventions recorded: TAC01-CLDN18.2.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/